title: Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists.
abstract: The efficacy of omeprazole therapy (40 mg daily) in H2-blocker refractory severe reflux oesophagitis (Grade II-IV; Savary and Miller classification) was investigated in 61 patients. Mean duration of reflux disease and preceding H2-antagonist treatment were 4.3 years and 15 months, respectively. Healing rates at 4, 8 and 12 weeks were 48%, 80% and 92%, respectively. There was a correlation between severity of oesophagitis and duration of omeprazole therapy necessary for healing. Three patients (5%) required higher dosages than 40 mg for healing. Symptomatic responses paralleled healing. It is concluded that omeprazole is a highly effective drug for severe reflux oesophagitis not responding to H2-blocker treatment and that 40 mg daily is the optimal dose.
authors.affiliation: Department of Medicine, Philipps-University, Marburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Koop
authors.forename: J
authors.initials: J
authors.lastname: Hotz
authors.forename: G
authors.initials: G
authors.lastname: Pommer
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: R
authors.initials: R
authors.lastname: Arnold
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004351:Drug Resistance; D016099:Endoscopy, Gastrointestinal; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D006635:Histamine H2 Antagonists; D009853:Omeprazole